Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) EBITDA Margin (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed EBITDA Margin for 7 consecutive years, with 3020.28% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin fell 201720.0% to 3020.28% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 785.68% through Dec 2025, down 30814.0% year-over-year, with the annual reading at 785.66% for FY2025, 30812.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 3020.28% at Kymera Therapeutics, down from 2928.84% in the prior quarter.
  • The five-year high for EBITDA Margin was 26.04% in Q4 2023, with the low at 3020.28% in Q4 2025.
  • Average EBITDA Margin over 5 years is 695.12%, with a median of 382.06% recorded in 2022.
  • The sharpest move saw EBITDA Margin surged 29812bps in 2021, then crashed -201720bps in 2025.
  • Over 5 years, EBITDA Margin stood at 225.3% in 2021, then increased by 7bps to 210.06% in 2022, then surged by 88bps to 26.04% in 2023, then plummeted by -3752bps to 1003.08% in 2024, then crashed by -201bps to 3020.28% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 3020.28%, 2928.84%, and 664.67% for Q4 2025, Q3 2025, and Q2 2025 respectively.